Patients suffering from acute or chronic lung diseases are unable to sufficiently clear the carbon dioxide generated by metabolic processes in their bodies by exhaling it via the lung. CCORE, a spinoff of the Medical University of Vienna, is developing new methods for minimally invasive blood purification. The company is developing a solution to prevent lung injury caused by invasive ventilation methods or even avoid, or largely reduce, the need for invasive ventilation.
Angel Valve Vienna is dedicated to the development of sophisticated treatment concepts for mitral valve repair. With the current lead product, the Mitral Butterfly® implant, the company focuses on the minimally invasive intervention of mitral regurgitation, a condition that affects 2-3% of the world´s population.
AFreeze uses cryotechnology for the treatment of cardiac arrhythmia. The company’s technology is a device that shock-freezes tissue in the left atrium via a catheter, thereby eliminating all three possible mechanisms of arterial fibrillation.
EMCOOLS Medical Cooling Systems develops and markets novel non-invasive cooling devices to benefit neurologic outcomes after ischaemic events such as myocardial infarction, stroke and cardiac arrest. In pre-hospital and in-hospital settings, EMCOOLS products deliver a perfect synergy of ease of use and best-in-class product performance.
Miracor Medical Systems is commercialising a new technology for improving outcomes for heart attack patients. Using an approach called Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO), the method seeks to improve blood flow in the heart tissue and improve overall heart function after a severe heart attack.